跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SANDOZ DAPAGLIFLOZIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SANDOZ DAPAGLIFLOZIN
Authorized
STANDARD
SANDOZ DAPAGLIFLOZIN
Sandoz Canada, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
96df9daef0a75de0
Company
Sandoz Canada, Inc.
Type
Standard
Approval Details
Approval Id
96df9daef0a75de0
Drug Approval Canada Name
SANDOZ DAPAGLIFLOZIN
Product Name
SANDOZ DAPAGLIFLOZIN
Status
Marketed
Status Date
2023-05-17
Original Market Date
2023-05-17
Din
02518740
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.18
Atc Original
A10BK01 DAPAGLIFLOZIN
Atc Name
a 10 bk 01
Aig Number
0156370002
Company Name
Sandoz Canada, Inc.
Company Address
4600 Rue Armand-Frappier, Saint-Hubert, Quebec, Canada, J3Z 1G5
Company Detail Path
/organization/sandoz-canada-inc
Company Information
Pharmaceutical Company Name
Sandoz Canada, Inc.
Country Name
Canada
Website
http://www.sandoz.ca
Active Ingredients
DAPAGLIFLOZIN
10 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
96df9daef0a75de0
Type
Standard
Back to Health Canada Approvals